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Background: The Clinical High Risk state for Psychosis (CHR-P) has become the 
cornerstone of modern preventive psychiatry. The next stage of clinical advancements 
rests on the ability to formulate a more accurate prognostic estimate at the individual 
subject level. Individual Participant Data Meta-Analyses (IPD-MA) are robust evidence 
synthesis methods that can also offer powerful approaches to the development and 
validation of personalized prognostic models. The aim of the study was to develop and 
validate an individualized, clinically based prognostic model for forecasting transition to 
psychosis from a CHR-P stage.
Methods: A literature search was performed between January 30, 2016, and February 
6, 2016, consulting PubMed, Psychinfo, Picarta, Embase, and ISI Web of Science, using 
search terms (“ultra high risk” OR “clinical high risk” OR “at risk mental state”) AND [(conver* 
OR transition* OR onset OR emerg* OR develop*) AND psychosis] for both longitudinal 
and intervention CHR-P studies. Clinical knowledge was used to a priori select predictors: 
age, gender, CHR-P subgroup, the severity of attenuated positive psychotic symptoms, the 
severity of attenuated negative psychotic symptoms, and level of functioning at baseline. 
The model, thus, developed was validated with an extended form of internal validation.
Results: Fifteen of the 43 studies identified agreed to share IPD, for a total sample size of 
1,676. There was a high level of heterogeneity between the CHR-P studies with regard to 
inclusion criteria, type of assessment instruments, transition criteria, preventive treatment 
offered. The internally validated prognostic performance of the model was higher than chance 
but only moderate [Harrell’s C-statistic 0.655, 95% confidence interval (CIs), 0.627–0.682].
Conclusion: This is the first IPD-MA conducted in the largest samples of CHR-P ever 
collected to date. An individualized prognostic model based on clinical predictors available in 
clinical routine was developed and internally validated, reaching only moderate prognostic 
performance. Although personalized risk prediction is of great value in the clinical practice, 
future developments are essential, including the refinement of the prognostic model and 
its external validation. However, because of the current high diagnostic, prognostic, and 
therapeutic heterogeneity of CHR-P studies, IPD-MAs in this population may have an 
limited intrinsic power to deliver robust prognostic models.
Keywords: clinical high risk, psychosis, schizophrenia, individual patient data meta-analysis, prognosis, risk 
prediction
INTRODUCTION
Clinical research on early recognition and intervention of 
psychotic disorders has enormously expanded over the past two 
decades (1). There is converging evidence that individuals with 
an elevated risk for psychosis, commonly termed as at Clinical 
Risk for Psychosis [CHR-P; or as “ultra high risk” (UHR) or “at‐
risk mental state” (ARMS)], can be identified prior to the onset 
of a psychotic episode. CHR-P criteria are based by the presence 
of attenuated psychotic symptoms, brief and intermittent 
psychotic symptoms with spontaneous remission, or genetic 
risk for psychosis (2–4), usually combined with functional 
impairments and help-seeking behavior (5). CHR-P individuals 
accumulate several risk factors for psychosis (6) and have a meta-
analytical risk of developing psychosis of 20% [95% confidence 
interval (95% CI) 17%–25%] at 2 years [for details, see Table 4 
in Fusar-Poli et al. (7)] while they are not an increased risk for 
developing non-psychotic mental disorders (8). The level of risk 
for psychosis is highest in those with a short-lived psychotic 
episode, intermediate in those with attenuated positive psychotic 
symptoms and lowest in those at genetic risk (9). Overall, the 
meta-analytical prognostic performance of the CHR-P assessment 
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is excellent [area under the curve (AUC) of 0.9 at 38 months] (10) 
and comparable to that of prognostic models used in other branches 
of somatic medicine. Despite these achievements, to date, the 
formulation of a prognosis in CHR-P individuals has been limited 
to group-level predictions. In light of the recent emergence of 
precision medicine approaches, it is thus important to develop and 
validate prognostic models that can calculate a personalized risk 
rather than a group-level global risk estimate. Prognostic modeling 
combines multiple predictor variables with their relative weight to 
estimate the risk or probability that an outcome or specific event 
will occur in an individual patient (11) and is often used in medical 
sciences, such as cardiology or oncology [e.g., Refs. (12, 13)]. 
The calculated individual risks could then be utilized by the 
caregiver to inform treatment decisions.
More recently, prognostic models have entered clinical 
psychiatry [for a methodological review, see Fusar-Poli et al. 
(14)]. A systematic review has identified seven prognostic 
models for CHR-P populations, most of which suffer from 
methodological weaknesses, such as the use of suboptimal model 
building methods, small sample sizes, and the lack of internal or 
external validation (15). Several recommendations for building 
robust prognostic models in CHR-P populations were made, 
including the use of large sample sizes, appropriate events per 
variable ratios, the selection of a priori predictors on the basis 
of clinical knowledge or the use of automated selection features 
through machine-learning methods, and the essential need to 
present validated (internal and external) measures of prognostic 
performance (14). Some examples of robust prognostic subject-
level models for CHR-P populations include the nothern american 
prodrome longitudinal study (NAPLS) risk calculator by Cannon 
et al. (16) [which has been externally validated (17)], the pretest 
risk enrichment stratification algorithm by Fusar-Poli et al. (18) 
(which has been externally validated), the transdiagnostic risk 
calculator by Fusar-Poli et al. (19) [which has been externally 
validated twice (20) and implemented in clinical routine (21)], and 
the functional outcome prognostic model by Koutsouleris et al. 
(22) (internally validated). Yet, the key create-limiting step toward 
implementation of prognostic models into CHR-P clinical routine 
is the availability of predictors. Biological and neurophysiological 
data require more expensive and intrusive assessment methods 
which are not always available in clinical practice, limiting the 
clinical utility of these models. Rather, neurobiological-based 
prognostic models can further refine the prediction of outcomes 
when used in a stepped sequential framework (23), after simpler 
prognostic models are applied.
We present here an innovative approach for developing 
risk prediction models for CHR-P individuals that are based 
on clinical predictors routinely collected as part of clinical 
practice. We developed a multivariable (i.e., including several 
predictors) risk estimation model through re-analyzing 
original individual raw data, requested from systemically 
sought research groups (24), through an individual patient 
data meta-analysis (IPD-MA). Prognostic models developed 
from an IPD-MA offer several unexplored advantages, such 
as large sample sizes, which are of core importance in the 
case of rare events, such as the transition to psychosis from 
CHR-P stage (25). Moreover, because an IPD-MA leverages 
the variation in the characteristics of the CHR-P included, it 
can potentially increase the generalizability of the prognostic 
model. Furthermore, a prognostic model derived from 
IPD-MA can statistically take into account the differences 
in prognostic parameters (such as intercepts and predictor-
outcome associations) across the included original studies and 
can explore under which circumstances the prognostic model 
predicts optimally (26). Despite these potentials, no IPD-MA 
has ever been conducted in the CHR-P field.
The primary aim of the current study was to develop and 
validate an individualized, clinically based prognostic model for 
forecasting transition to psychosis from a CHR-P stage using 
predictors that were selected on the basis of a priori clinical 
knowledge and that were available in clinical routine.
METHODS
Search Strategies
A systematic search strategy was performed to identify relevant 
original studies. First, an electronic search was performed in 
PubMed, Psychinfo, Picarta, Embase, and ISI Web of Science. The 
search was conducted between January 30, 2016, and February 6, 
2016. The following search terms were used: (“ultra high risk” OR 
“clinical high risk” OR “at risk mental state”) AND [(conver* OR 
transition* OR onset OR emerg* OR develop*) AND psychosis]. 
Second, the reference lists of the included articles were manually 
checked for studies not identified by the computerized search.
Selection Criteria
Inclusion criteria were as follows:
 (1) data reported in an original paper in a peer-reviewed journal;
 (2) involved CHR-P subjects 14 to 40 years old, defined according 
to established international criteria (1);
 (3) assessed attenuated positive and negative psychotic symptoms 
as well as level of functioning at baseline using standardized 
CHR-P measurements;
 (4) reported transition status at follow-up (events);
 (5) reported time to transition or time to last follow-up 
assessment.
Both longitudinal and intervention studies were included. 
In the case of studies investigating heterogeneous patient 
populations, only CHR-P individuals were selected for the 
analysis. Furthermore, CHR-P individuals who were not meeting 
the age criterion defined above were excluded from the analysis, 
as well as CHR-P patients who were already psychotic at baseline 
as documented in the corresponding articles.
To achieve a high standard of reporting, we adopted the 
Preferred Reporting Items for Systematic Reviews and Meta-
analyses Guidelines-Individual Patient Data (PRISMA-
IPD), (27) as well as the statement transparent reporting of 
a multivariable prediction model for individual prognosis or 
diagnosis (TRIPOD) (28). The meta-analysis was registered 
in the PROSPERO database for systematic reviews and meta-
analysis (CRD42017071176).
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Selection of Predictors
For developing and validating a prediction model, it is 
recommended to select prognostic variables a priori based on 
earlier research (28) and clinical knowledge (14). To develop a 
model that is readily applicable in clinical practice, the selected 
predictors were limited to those routinely assessed in CHR-P 
clinics and involved demographical and clinical predictors. The 
a priori selected predictors were age, gender, CHR-P subgroup 
(attenuated psychotic symptoms, brief and limited intermittent 
psychotic symptoms, genetic risk, and deterioration syndrome), 
baseline severity of attenuated positive and negative psychotic 
symptoms, and level of functioning. The a priori clinical 
rationale for selecting these predictors is given below. The first 
predictor is age: in general, youth in their late teens and early 
20s have the highest risk of developing psychosis (29) and a 
meta-analysis revealed that older CHR-P individuals had a 
significant higher risk for developing a psychotic episode (30). 
Another recent umbrella review found that those aged 15 to 35 
years have a strong factor associated with an increased risk of 
psychosis (31). The same umbrella review found that gender, 
the second predictor in our model, has a clear association 
with an increased risk of psychosis (31). In fact, gender has 
already been used as predictor in other prognostic models 
developed for CHR-P populations (19). The third predictor 
was the severity of attenuated positive psychotic symptoms, 
such as delusions, unusual thought content, and suspicion, 
which are the most studied and established predictors in 
CHR-P field and already used by previous prognostic tools 
in this group (16). Furthermore, a recent meta-analysis of 33 
studies, involving a total of 4,227 CHR-P individuals, showed 
different levels of the risk for psychosis onset, where persons 
with brief and limited intermittent psychotic symptoms 
had the highest risk of transition, followed by those with 
attenuated positive psychotic symptoms, and by those with 
genetic risk and deterioration syndrome who had the lowest 
risk (9). Therefore, the CHR-P subgroups were included as 
three independent predictors, recording whether or not the 
criteria of each distinctive risk group were met. Attenuated 
negative psychotic symptoms encompass social amotivation 
(apathy, anhedonia, asociality) and expressive deficits (alogia, 
diminished emotional expression) (32) and were selected as the 
seventh predictor. Attenuated negative psychotic symptoms 
were predictive of a subsequent psychotic disorder in CHR-P 
individuals (33, 34). The last predictor variable was the level of 
functioning at baseline: a meta-analysis in CHR-P individuals 
confirmed that functioning is a strong predictor of transition 
to psychosis (35).
Data Collection
Abstracts were screened independently by two reviewers (AM 
and NB or MP). Each article was assessed individually, and any 
disagreements resolved by discussion with a third reviewer. 
Subsequently, all corresponding authors of the eligible studies 
identified were contacted to request anonymized individual 
patient data and regarded as non-responders when no reaction 
was received after two reminder emails.
Data Extraction
From each individual patient, the following variables were 
included: gender, the baseline age of participant, CHR-P group, 
the severity of attenuated psychotic positive and negative 
symptoms, level of functioning, transition status at follow-up, and 
duration of the follow-up period. To get a better understanding of 
possible factors that may have influenced the performance of the 
prognostic model across the different studies, as well as to detect 
factors that may have contributed to the study heterogeneity, 
we also collected for each study additional data. These data are 
related to the inclusion period, inclusion strategies, inclusion 
and exclusion criteria, the psychometric criteria employed to 
define transition to psychosis and the type of CHR-P assessment 
instruments [for a comparative analysis of CHR-P assessment 
instruments, see Fusar-Poli et al. (36)], and the instruments 
applied to assess symptoms and functioning.
Data Storage
All data were anonymized by the researchers of the original 
studies and therefore not re-identifiable to an individual patient 
by the current investigators. All cleaned data sets were stored 
on a secured server in their original formats and converted to 
a master data set. Data were inspected on unusual outliers via 
range check of the all included variables.
Data Transformation
Studies vary in the CHR-P instruments assessing the severity 
of attenuate positive psychotic symptoms, attenuated negative 
psychotic symptoms, and functioning. Thus, to make it clinically 
applicable, only one measurement was selected in the model as 
the primary parameter. The selection of the assessment measure 
was defined a priori on the basis of clinical reasoning.
Missing Data
Missing data were imputed according to Multiple Imputations 
with Chained Equations (MICE) with 50 iterations sets. As 
recommended by White and Royston (37), the event indicator 
and Nelson-Aalen estimator of cumulative baseline hazard 
were included in the imputation model. Also, the study name 
of the original data was included as a dummy factor to account 
for potential between-study heterogeneity. Rubin’s Rules were 
applied to combine the data from the imputation sets (38).
Risk of Bias Assessment in Individual 
Studies
The assessment of the methodological quality of each individual 
included study is an essential element in meta-analyses (27). 
The majority of the studies in this IPD-MA have a naturalistic 
observational design (N = 12). As such, we used the systematic 
review of Zeng et al. (39), which recommends the Newcastle-
Ottawa Scale (NOS) (40), a nine-item scale categorized into three 
dimensions, namely, selection, comparability, and outcome. 
Quality assessment of naturalistic and observational studies in 
meta-analyses is problematic. In fact, the key components of 
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studies to be assessed on the MOOSE’s recommendations were 
whether the outcome of interest was not present at the start of 
the study, the follow-up period of the study was long enough for 
the outcome to occur, and an adequate proportion of the subjects 
participated in the follow-up cohort (41). The minimal follow-up 
period in this IPD-MA was set at 12 months. Studies received a 
positive score for adequacy of follow-up cohort when they had a 
minimum follow-up rate of 50% to 80% in cohort studies or 80% 
in randomized controlled trials (RCTs) (42).
Primary Outcome
The primary outcome is the transition to psychosis (event) from a 
CHR-P stage. Transition to psychosis was defined according to the 
criteria of the Comprehensive Assessment of At Risk Mental State 
(CAARMS) (2), Structured Interview of Prodromal Symptoms/
Scale of Prodromal Symptoms (SIPS/SOPS) (3), Brief Psychiatric 
Rating Scale (BPRS) (43), Positive and Negative Syndrome 
Scale (PANSS) (44), or Structured Interview for Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (SCID-IV) 
(45). The CHR-P patient outcomes were recorded as transitioned 
to a psychosis, no transition, or lost to follow-up.
Data Analyses
Individuals with a complete follow-up assessment were 
compared with those lost to follow-up with an independent t test 
(continuous variables) or chi-square test (binary variables) for 
descriptive purposes. Collinearity of predictors was tested with 
the variance inflation factor (VIF) and estimated by the formula 
1/(1 − R2). An outcome of 4 or lower indicates a low indication of 
collinearity between the predictors (46).
A parametric survival model with a log-normal distribution 
for event times was computed (47). The evaluation of the model’s 
performance and generalizability was done with an extended 
form of internal validation, because of the lack of true external 
validation data. Therefore, an internal–external cross validation 
(IECV) technique was applied, which maximized the data 
available for both model development as well as model validation 
(26). With the IECV, all studies (M) minus one study were used as 
a derivation set to develop a prediction model, and the remaining 
set is used for its external validation. This was repeated for each 
data set, leading to M scenarios to investigate consistent model 
performance, which was combined by applying Rubin’s Rules 
(38). All discovered studies were utilized in the development and 
validation of the model. A t test calculated the significance of the 
final beta coefficients of the predictors.
The model performance was estimated by calculating its 
discrimination and calibration. Discrimination referred to the 
model’s ability to separate CHR-P individuals who transitioned 
to psychosis versus those who did not transition. For each study, a 
bar graph with the frequency distribution of predicted survival of 
the survival groups was presented, for both 12 months as well as 24 
months. For both 12 and 24 months, the bar graph showed 10 risk 
groups, which each represented an equal number of individuals. 
The distribution of the risk groups, which ranged from 0 (no 
chance of survival, i.e. transition to a psychosis) until 100 (100% 
chance of survival, so no transition to psychosis) was determined 
by the observed survival per study. A well-discriminating model 
shows a high overlap between the predicted survival and the 
observed survival in the different risk categories (48). Moreover, 
Harrell’s C statistics with its 95% CI was calculated per study, 
which referred to the overall probability that the model estimates 
a higher risk for the CHR-P individual that does develop psychosis 
compared with a person that does not. Values of C-statistics 
higher than 0.5 (random prediction) and lower than 0.6 are 
considered “poor”; from 0.6 and 0.7 are considered “moderate”; 
from 0.7 to 0.8, “adequate”; from 0.8 to 0.9, “excellent”; and above 
0.9, “outstanding,” up to 1 (perfect prediction). The C-statistics 
of all individual studies was plotted in a forest plot, with the 
95% CI indicating a possible statistical difference from random 
prediction. Furthermore, for each study, the calibration of the 
model was calculated, which referred to the agreement between 
the observed and the predicted outcomes (48) and was presented 
with its 95% CI for each individual article in a forest plot. The 
linear predictor is calculated according to the coefficients of the 
model and included as a covariate in a Cox model. The slope of 
the linear predictor is the calibration slope. The calibration plot 
can be viewed as a measure of fit of the prognostic model in the 
CHR-P population: when a study’s 95% CI included the value of 1, 
it indicated a fit, whereas a 95% CI not containing a score of 1 
implied a serious misfit of the model, suggesting that adjustments 
of the model’s intercepts should be considered.
The CHR-P studies differed with regard to study design, 
inclusion period, recruitment strategies, inclusion and exclusion 
criteria, transition criteria, CHR-P assessment instruments, 
and treatments offered. These characteristics were expected to 
influence the effects of the prognostic model in this IPD-MA. 
In meta-analyses, heterogeneity is examined with the Q-statistic 
and I2 Index (24). However, in studies that develop prediction 
models based on IPD-MA, the extent of heterogeneity is better 
quantified by studying the 95% prediction intervals (49).
All statistical analyses were conducted using R version 4.2.2 
(50) and used the following packages: foreign, mice, micemd, 
Hmsic, VIM, jomo, flexsurv, metamisc, rms, and pec.
RESULTS
Studies and Participants
A total of 2,176 papers were identified by the literature 
search and 43 were deemed eligible for the IPD-MA. The 
corresponding authors of the 43 studies were contacted, 
of which 15 agreed to participate and shared all necessary 
individual patient data needed for the model (see Figure 1). Of 
the remaining authors, seven authors replied to work on the 
same subject, two were not able to share the essential data, and 
nineteen authors did not reply at all. These 28 studies related 
to a total of 2,815 CHR-P individuals (62.7% of CHR-P eligible 
subjects), of whom 475 transitioned to psychosis (16.9% of the 
eligible yet not included subjects). There is a selection bias in 
that the current IPD-MA included 1,676 CHR-P individuals, 
of whom 386 developed psychosis. This corresponded to 37.3% 
of all the CHR-P eligible participants.
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The participating studies were Access, Detection And 
Psychosocial Treatment (ADAPT) (51), Clinic for Assessment 
of Youth at Risk (CAYR) (52), Dutch Prediction of Psychosis 
Study-Amsterdam (DUPS-A) (53), Early Detection and 
Intervention Evaluation-Netherlands (EDIE-NL) (54), Early 
Detection and Intervention-United Kingdom (EDIE-UK) (55), 
Früherkennung von Psychosen (FePsy) (56), Früherkennungs- 
und Therapiezentrum für psychische Krisen (FETZ) (57), 
Green Program for Recognition and Prevention of Early 
Psychosis (GRAPE) (58), Integrative Neuroimaging Studies in 
Schizophrenia Targeting for Early intervention and Prevention 
(IN-STEP) (59), Outreach and Support in South London (OASIS) 
(60), Personal Assessment and Crisis Evaluation (PACE) (61), 
Programme of Recognition and Therapy (PORT) (62), ROME 
(63), Sendai ARMS and First Episode clinic (SAFE) (64), and 
Dutch Prediction of Psychosis Study-Utrecht (DUPS-U) (65).
Furthermore, for each included study, we checked whether 
CHR-P individuals met the inclusion criteria. CHR-P individuals 
younger than 14 years were removed from the data set: ADAPT 
(N = 2), CAYR (N = 1), DUPS (N = 4), EDIE-NL (N = 1), PACE 
(N  = 1), Rome (N = 19), and DUPS-U (N = 14), as well as 
participants older than 40 years: FePsy (N = 10) and IN-STEP 
(N = 1). Subjects with an elevated risk for psychosis but not 
meeting the established CHR criteria were excluded: FePsy 
(n = 30), FETZ (N = 30), INSTEP (N = 4), and DUPS-U (N = 4). 
Similarly, subjects who were already psychotic as reported in the 
corresponding article were filtered out: EDIE-NL [psychotic at 
inclusion (N = 4), history of psychosis (N = 1)]. Subjects’ data 
FIGURE 1 | Flow chart of the study.
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were censored to the primary study protocol-stated follow-up 
period: FePsy (N = 1) and CAYR (N = 4).
Because of these procedures, a final sample of 1,676 
individuals fulfilled the inclusion criteria and was included in the 
IPD-MA. Key details of the included studies are summarized in 
Table 1, and a more comprehensive information on each study is 
included in Supplement IV.
An overview of the comparison of study characteristics is 
presented in Table 2. The CHR-P studies worldwide participated 
in the study, and majority of the studies took place in Europe 
(53–57, 60, 62, 63, 65). Three studies concerned an RCT (51, 54, 
55), one study had a mixed design of both RCT and naturalistic 
observational design (61), whereas all the others had a naturalistic 
observational design. The earlier studies started including 
individuals in 1993 (61), whereas the later studies started including 
in 2013 (60). The inclusion period varied between 1 year (52) 
and 13 years (61). The smallest study contained 19 subjects (63), 
whereas the largest study contained over 400 individuals (61). 
Despite methodological differences, one inclusion criterion was 
shared by all studies, namely, meeting the clinical high-risk criteria 
of at least one of the high-risk groups [genetic risk and deterioration 
(GRD), attenuated psychotic symptoms (APS), or brief limited 
psychotic symptoms (BLIPS)]. Eleven studies had additional age 
criteria (52, 54, 55, 58–64), one study included only participants 
with a minimum of 9 years of education (58); and as additional 
criterion for another study, individuals should have no history of 
antipsychotic medication for over 16 weeks (59). There was a greater 
variety in the applied exclusion criteria, with only the EDIE-UK 
(55) study that did not exclude subjects in case of a known organic 
cause for the presentation of prodromal symptoms. Twelve studies 
excluded individuals with either a current or a lifetime psychotic 
condition (51, 54, 58, 60–68). Ten studies excluded individuals with 
lower intellectual capacities (51, 52, 54, 56, 57, 59, 60, 62, 64, 65), 
five studies excluded individuals in case of substance use or abuse 
(52, 59, 60, 63, 64). Current or a history of antipsychotic medication 
was an exclusion criterion in six studies. Two studies excluded 
individuals with insufficient competence of the primary language 
(54, 66). The presence of a pervasive developmental or autism 
spectrum disorder was an exclusion criterion in two studies (52, 59). 
In one study, a history of electroshock therapy (59), withdrawing 
their willingness to be followed by the service (60) or suicide risk 
due to personality disorder (64) was an exclusion criterion. In the 
final database, the mean follow-up time was of 32.37 months (SD, 
31.59 months), and there were 386 (23.0%) transitions to psychosis 
(events). Therefore, the final event per variable ratio was 1:48, 
which is below the threshold recommended for building robust 
prognostic models (14).
Eight of 15 studies launched special information campaigns, 
either targeting only potential sources of participant referrals or 
the general public (51, 52, 55, 60, 62, 64, 66, 67). The campaigns 
differed in their elaborateness: from a website and folders to 
workshops, letters in newspapers, and advertisement on radio 
and television. All studies included individuals that were referred 
to them, but a few studies combined this with the option of self-
referral (52, 62), referral by a close friend or family member 
(52) or screening in a help-seeking population (54). Six studies 
offered additional treatment, such as case management, cognitive TA
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behavioral therapy, psychoeducation for the CHR individuals, as 
well as for family, medication, sport, and nutrition groups (52, 
60–62, 66, 64). Information on specific treatments that were 
offered was only available for RCTs, and most studies did not 
keep detailed records of offered interventions.
With regard to the assessment of CHR-P, symptoms, and 
functioning, four instruments were applied to determine whether 
an individual met the CHR criteria, namely, PANSS (44), CAARMS 
(2), the Basel Screening Instrument for Psychosis (BSIP) (4), and 
the SIPS/SOPS (3). Positive psychotic symptoms were assessed with 
five different instruments: PANSS (44), CAARMS (2), BPRS (43), 
SIPS (69), and the Scale of Assessment of Positive Symptoms (SAPS) 
(70). Negative psychotic symptoms were measured with four scales: 
TABLE 2 | Summary of study characteristics.
N (studies) % of studies % of total 
sample
Continent:
Europe
Australia
Northern America
Asia
9
1
2
3
60.0
6.7
13.3
20.0
48.8
24.8
13.4
13.1
Design:
Naturalistic observational
RCT
Mixed
11
3
1
73.3
20.0
6.7
82.0
18.1
24.8
Start inclusion period:
Before 2000
2000–2005
2005–2010
2010–
3
4
5
3
20.0
26.7
33.3
20.0
37.9
11.9
31.9
10.6
Inclusion period—duration:
1 year
1–2 years
2–3 years
>3 years
1
5
4
5
6.7
33.3
26.7
33.3
10.5
22.3
17.1
48.6
Information campaigns
Yes
No
8
7
53.3
46.7
50.0
50.0
Inclusion strategies
Referral
Mixed 
12
3
80.0
20.0
71.4
28.6
Inclusion criteria: in additional 
to CHR-group:
Age at inclusion
A minimum of 9 years of 
education
No history of antipsychotic 
medication for over 16 weeks 
10
1
1
66.7
6.7
6.7
74.1
3.6
3.2
Exclusion criteria:
Organic cause for prodromal 
symptoms
Current or lifetime psychosis
Intellectual functioning
Substance use
Current or history of 
antipsychotic medication
Language requirements
Diagnosed with pervasive 
developmental disorder or 
autism spectrum
A history of electroshock therapy
Not help seeking individuals
Suicide risk due to personality 
disorder
14
12
11
5
6
2
2
1
1
1
93.3
80.0
73.3
33.3
40.0
13.3
13.3
6.7
6.7
6.7
96.7
82.9
67.1
24.2
53.8
19.5
13.7
3.0
3.0
6.3
Assessment of ultra high risk:
SIPS/SOPS
CAARMS
PANSS
BSIP
7
6
1
1
46.7
40.0
6.7
6.7
26.1
63.1
3.5
7.9
Assessment of positive 
psychotic symptoms:
BPRS
CAARMS
SIPS/SOPS
PANSS
SAPS
3
3
5
3
1
20.0
20.0
33.3
20.0
6.7
43.2
21.1
21.1
13.9
3.6
(Continued)
TABLE 2 | Continued
N (studies) % of studies % of total 
sample
Assessment of negative 
psychotic symptoms:
SANS
PANSS
SIPS/SOPS
CAARMS
4
4
4
3
26.7
26.7
26.7
30.0
46.8
13.6
18.2
21.1
Assessment of functioning:
GAF
SOFAS
mGAF
cGAS
QLS
9
3
1
1
1
60.0
20.0
6.7
6.7
6.7
66.3
27.7
1.5
1.0
3.6
Transition criteria:
CAARMS
SIPS/SOPS
PANSS
BPRS
SCID-I
5
4
3
2
1
46.7
26.7
13.3
13.3
6.7
56.3
8.7
14.0
17.5
3.6
Sample size:
<50
50–100
100–150
150–200
>200
3
5
3
3
1
20.0
33.3
20.0
20.0
6.7
5.6
17.4
20.6
31.8
24.7
Transition rate:
<10%
10–20%
20–30%
30–40%
>40%
2
4
7
1
1
13.3
26.6
26.7
6.7
6.7
13.4
27.6
46.5
3.0
9.6
Treatment:
CBT (RCT)
Additional treatment
None 
3
6
6
20.0
40.0
40.0
18.1
59.0
23.1
BPRS, Brief Psychotic Rating Scale; BSIP, Basel Screening Instrument for Psychosis; 
CAARMS, Comprehensive Assessment of At-Risk Mental State; CBT, Cognitive 
Behavioral Therapy; cGAS, children Global Assessment Scale; CHR, clinical high risk; 
GAF, Global Assessment of Functioning scale; mGAF, modified Global Assessment 
of Functioning scale; PANSS, Positive and Negative Syndrome Scale; QLS, Quality 
of Life Scale; RCT, Randomized Controlled Trial; SANS, Scale for the Assessment of 
Negative Symptoms; SCID-I, Structured Clinical Interview for DSM-IV; SIPS/SOPS, 
Structured Interview of Prodromal Symptoms/Scale of Prodromal Symptoms.
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PANSS (44), Scale of Assessment of negative symptoms (SANS) 
(71), CAARMS (2), and the SIPS (3). Functioning was assessed with 
five scales, namely, the Global Assessment of Functioning (GAF) 
(72), the Modified-Global Assessment of Functioning (m-GAF) 
(73), the Children Global Assessment Scale (cGAS) (74), the Social 
and Occupational Functioning Scale (SOFAS) (75), and the Quality 
of Life Scale (QLS) (76). Transition to psychosis was determined 
with four different transition criteria: CAARMS [five studies (52, 
54, 60, 61, 64)], SIPS/SOPS [four studies (51, 59, 63, 65)], PANSS 
[three studies (53, 55, 62)], BPRS [two studies (56, 57)], and SCID-1 
[one study (58)].
Quality Assessment of Individual  
CHR-P Studies
All CHR-P studies received the maximum score of 4 for assessing 
the study quality with the NOS (40): an adequate check that outcome 
is not present at the start of the study, an adequate duration of the 
follow-up period, and an adequate proportion of participants in the 
follow-up assessments (see Supplements 1 and 2). The three RCTs 
additionally received an extra point for blind assessments.
Data Cleaning and Preparation
Missing Data and Multiple Imputations
In the original sample, 78.6% had data on all variables. There 
were missing data with regard to attenuated negative psychotic 
symptoms (7.2%), functioning (6.6%), attenuated positive 
psychotic symptoms (4.8%), CHR-P group (4.2%), age (<0.1%), 
and sex (<0.1%). For the individuals, 3.8% were omitted from 
the analyses because of missing of follow-up data. There were no 
differences between CHR-P subjects with and without follow-up 
with regard to age, gender, type of CHR-P subgroup, attenuated 
negative psychotic symptoms, and functioning at baseline. 
Only the severity of attenuated positive psychotic symptoms at 
baseline was significantly higher for CHR-P individuals without 
follow-up (t = −6.244, df = 1,563, p < .001).
As noted above, the 15 included CHR-P studies had applied a 
variety in assessment instruments with regard to attenuated positive 
psychotic symptoms, attenuated negative psychotic symptoms, 
and functioning (see Table 1). All measurements were tested as 
the core parameters on the basis of the protocol, yet, although 
other instruments were applied in more individuals, attenuated 
negative psychotic symptoms—total score SIPS, attenuated 
positive psychotic symptoms—total score SIPS and GAF were 
selected because these had the best predictive performance. SIPS/
SOPS is a frequently used instrument in the enclosed studies 
and is one of the golden standard measurements for positive 
and negative psychotic symptoms in CHR research (77). For 
functioning, the primary parameter is the frequently applied GAF 
(72). However, because the SIPS were only applied by 18.2% and 
the GAF by 66.3% of the individuals, there were missing data for 
81.8% (attenuated positive and negative psychotic symptoms) and 
33.7% (functioning). Multiple imputations were performed with 
50 iteration sets. The data from the variables age, gender, GRD, 
APS, BLIPS, and functioning (GAF) were used to predict the 
missing SIPS-positive and -negative psychotic symptoms scores. 
The imputations diagnostics are presented in Supplement III.
Testing Collinearity
An overview of the estimated VIFs is presented in Table 3. 
Overall, the majority of the predictor variables showed a VIF 
close to 1, indicating low shared variance with the other variables. 
However, the three CHR-P subgroups showed a high level of 
collinearity. To investigate the influence of the collinearity, all 
three predictors were one-by-one subsequently omitted from 
the analysis, leading to a drop in VIF scores of below three, yet 
barely influencing the outcome of the produced model. Given 
our aim to develop a prognostic model in which all predictors are 
assessed for their relative contribution to risk, these predictors 
were retained in further analysis, in line with the methodological 
recommendations (14).
Development and Validation  
of the Prognostic Model
A parametric survival model with a log-normal distribution 
is fitted for event times (47): transition to psychosis from a 
CHR-P stage and time to transition. Supplement V displays 
the discriminative performance of the prognostic model in the 
individual studies at 12 and 24 months. Figure 2 shows a forest 
plot with the 95% CI of the Harrell’s C-statistics of the prognostic 
model per study and the overall C-statistics.
The C-statistic of the model was 0.655 with a 95% CI of 0.627 
to 0.682 and (approximate) 95% prediction interval of 0.614 to 
TABLE 3 | Predictor variables and accompanying VIF. 
Dependent
Gender Age GRD APS BLIPS Pos Sx Neg Sx Functioning
In
de
pe
nd
en
t
Gender — 1.029 1.028 1.028 1.028 1.028 1.005 1.028
Age 1.021 — 1.022 1.022 1.020 1.012 1.016 1.022
GRD 7.857 7.875 — 1.026 1.599 7.877 7.877 7.877
APS 15.127 15.157 1.975 — 1.790 15.122 15.162 15.142
BLIPS 9.848 9.848 2.004 1.165 — 9.851 9.870 9.855
Positive Sx 1.415 1.404 1.419 1.415 1.416 — 1.208 1.418
Negative Sx 1.833 1.867 1.879 1.879 1.879 1.599 — 1.339
Functioning 1.586 1.589 1.590 1.588 1.587 1.589 1.133 —
APS, attenuated psychotic symptoms; BLIPS, brief limited psychotic symptoms; GRD, genetic risk and deterioration; Sx, symptoms; VIF, variance inflation factor.
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0.695. Inspection of the forest plot showed that the prognostic 
performance in the larger studies reached an adequate level, 
with C-statistics of around 0.700 and 95% CI between 0.54 and 
0.87 (52, 54, 56, 57, 61, 62). This is also visible in the boxplots 
of the individual studies (see Supplement V): the proportion 
of predicted survival per risk group is relatively equal to the 
observed proportion, meaning that the model can adequately 
discriminate between CHR-P individuals with a higher versus 
lower risk of developing psychosis (one survival). Yet, smaller 
studies have lower discriminative adequacy: in the forest plot, 
the 95% CIs of these studies were broad and included 0.5, which 
indicated that the model did not discriminate better than chance.
The calibration slope of the model in the individual CHR-P 
studies, as well as overall calibration, is displayed in Figure 3.
FIGURE 3 | Forest plot of the external validation of calibration slope and its 95% CI in the individual studies.
FIGURE 2 | Forest plot of the discriminative ability of the model in the individual studies and its 95% CI, assessed with the C-statistics.
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The internal–external validation results for the calibration 
slope gives an overall estimate of 0.886 (95% CI, 0.745–1.022), 
which indicated that at 2 years, the predicted probabilities, on 
average, vary too much. Because the 95% CI includes 1, the 
overall calibration slope yields as non-significant. Calibration 
slopes of the individual studies not overlapping with 1 indicate 
no need for recalibration. Inspection of the forest plot showed 
that all studies overlapped with 1, which indicated that the 
prognostic model calibrates sufficiently well, and there are no 
direct indications that the parameters of the model should be 
adjusted with shrinkage methods.
Final Model
Table 4 presents the final model with its intercepts; all included 
predictors have a significant contribution to the prediction, as 
tested with an independent sample t test. The scale parameter 
is 2.119.
Prognostic Prediction for Individual  
CHR-P Patients
With a parametric survival model with a log-normal distribution 
for event times, a (cumulative) survival probability can be 
calculated for time (t) in CHR-P individual subjects, utilizing 
the linear predictor (5.777) and the earlier reported scale 
parameter (78).
The following formula that estimates the risk of psychosis 
(1 survival) for an individual patient derives from the model:
Risk of psychosis = 1 − (7.543 + 0.179 (sex = female) + −0.049 × 
(age)+.689 × (genetic risk and deterioration) + −0.370 × (attenuated 
psychotic symptoms = yes) + −0.738 × (brief limited intermittent 
psychotic symptoms = yes) + 0.006 × (functioning GAF) + −0.052 × 
(total score negative psychotic symptoms SIPS/SOPS) + −0.102 × 
(total score positive psychotic symptoms SIPS/SOPS)).
Case Study
Considering a 21-year-old female that meets the CHR-P 
criteria of brief intermittent psychotic symptoms, with baseline 
GAF score of 65, SIPS/SOPS attenuated negative psychotic 
symptoms total score of 13 and a SIPS/SOPS attenuated positive 
psychotic symptoms total score of 8, the predicted 2-year 
survival would be 0.835. This implies that her probability of 
developing psychosis within the first 2 years is 1 −.835 = .165, 
which is of about 16%.
Heterogeneity
The 95% prediction interval of the C-statistics (0.614–0.695) 
shows a moderate range, which indicates that there is substantial 
heterogeneity between the predictions of the model in the different 
studies. There is a larger amount of heterogeneity detectable with 
regard to the overall calibration slope which shows a rather large 
95% CI of 0.745–1.022. This is supported by the large variety 
in operationalization of symptoms in the different assessment 
instruments, as well as variety in outcome criteria.
DISCUSSION
The aim of this study was to develop and validate a prognostic 
model based on clinical predictors that are available in clinical 
routine for forecasting the onset of a psychotic episode in CHR-P 
individuals, using an IPD-MA. The predictors were selected a 
priori as recommended by state-of-the-art prognosis guidelines. 
The predictors encompassed two demographical predictors (age, 
gender) and six clinical predictors collected at baseline (genetic 
risk and deterioration syndrome CHR-P subgroup, attenuated 
psychotic symptoms CHR-P subgroup, brief and limited 
intermittent psychotic symptoms CHR-P subgroup, severity of 
attenuated positive psychotic symptoms, severity of attenuated 
negative psychotic symptoms, level of functioning) predictors. 
The overall model achieved a C-index of .655, indicating a 
modest subject-level ability to differentiate between CHR-P 
individuals with a high-risk likelihood that develop psychosis 
from those at lower risk. The overall calibration slope indicated 
that the model can significantly distinguish CHR-P individuals 
who convert to psychosis versus those who do not. Most of the 
included predictors showed a significant contribution to the 
model, with the exception of CHR-P group membership (which 
was characterized by high collinearity). The removal of these 
variables from the model indicated that the influence of this 
collinearity on the final model was non-significant and minor 
in magnitude.
TABLE 4 | Variables and intercepts of the final model.
Variable Intercept: T SE of Mean Sign. 95% confidence interval
Lower Upper
Intercept 7.543328648 51.792 .14565 <.001 7.251 7.836
Sex—female 0.179071582 13.247 .01352 <.001 0.152 0.206
Age −0.048979637 −42.162 .00116 <.001 −0.051 −0.047
APS—yes −0.369616434 −7.737 .04777 <.001 −0.466 −0.274
BLIPS—yes −0.738429338 −15.950 .04630 <.001 −0.831 −0.645
Functioning: GAF score 0.006634737 4.059 .00163 <.001 0.003 0.010
Negative psychotic symptoms: SIPS/SOPS—total score −0.054490819 −14.542 .00375 <.001 −0.062 −0.047
Positive psychotic symptoms: SIPS/SOPS—total score −0.092850985 −16.356 .00574 <.001 −0.105 −0.082
APS, attenuated psychotic symptoms; BLIPS, Brief Limited Psychotic Symptoms; GRD, Genetic Risk and Deterioration; SE, Standard Error; Sign, significance level; SIPS/SOPS, 
Structured Interview of Prodromal Symptoms/Scale of Prodromal Symptoms.
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This is the first IPD-MA and the largest clinical prediction 
modeling study conducted in the CHR-P field. Indeed, one of 
the main advantages of developing a prognostic model using 
an IPD-MA is the possibility of reaching large sample sizes, 
which enables the building of a more robust prediction model. 
Moreover, the model’s generalizability can be strengthened by 
the inclusion of several large data sets from all over the world. 
Ensuring appropriate representativeness of CHR-P samples is 
pivotal to developing robust prognostic models because of the 
severe sampling biases that affect this population (18, 79, 80). Our 
approach was partially successful. On one side we demonstrated 
that our a priori selected predictors did produce a prognostic 
model that forecasted the onset of psychosis at the individual 
subject level with an accuracy superior to chance (0.655). From 
a methodological point of view this confirms that preselecting 
predictors on the basis of previous knowledge and using all of 
them in the prognostic model is a robust way for developing risk 
prediction algorithms. On the other side, the level of accuracy 
was only moderate. This could be due to the fact that our IPD-MA 
combined CHR-P studies employing different definitions of 
predictors and outcomes, and that there were some missing 
data (81). Furthermore, to ensure a prognostic model that could 
easily be applied in clinical practice, we decided to use only one 
instrument per predictor (e.g., the SIPS and not the CAARMS, 
PANSS, SAPS, or BPRS, and the GAF and not the SOFAS, 
mGAF, cGAS, or QLS). This was prespecified at the PROSPERO 
protocol level. This decision resulted in missing data, which 
has to be considered as missing not at random (MNAR). The 
problem was particularly severe because this led to a rather high 
level of missing data (81.8% for the attenuated positive/negative 
psychotic symptoms and 33.7% for the level of functioning). 
Although the missing data were handled with the recommended 
multiple imputation techniques (82), it did imbalance the final 
prognostic model. These choices counterweight the moderate 
prognostic accuracy of our model because they facilitate its 
theoretical implementability in clinical routine. Scalability of 
prognostic models is an essential criterion that should be fully 
considered beyond the level of prognostic accuracy. In fact, even 
prognostic models that have a suboptimal (but clearly higher 
than random prediction) level of prognostic performance can 
be clinically useful if they can enter clinical routine at scale. For 
example, a prediction model has recently been developed and 
validated using a patient data and machine learning to predict 
treatment outcome in depression: the overall performance of this 
model was of a very similar moderate prognostic performance 
(0.65) (83).
The next stage would be to refine and improve this model. 
The first option would be to consider using advanced machine-
learning approaches. Yet, there is no strong evidence that these 
methods can deliver more robust and implementable prognostic 
models compared with a priori–defined statistical models. 
Interestingly, although the prognostic model described above 
leveraged machine learning methods, its overall prognostic 
performance was of a similar level than that of our current model 
(83). A recent systematic review conducted by methodologists 
showed no performance benefit of machine learning over logistic 
regression for clinical prediction models (84). However, it is 
possible that machine learning methods could demonstrate some 
clear advantages with the addition of multidimensional predictors 
encompassing neurobiological, genetic, and other modalities 
(14). The downside of multimodal approaches is that they tend 
to deliver more complex prognostic models at the expense of 
scalable implementability. This IPD-MA study also calls for more 
homogeneity in the CHR-P assessment instruments or at least 
more research in the development of converting formulas. This 
would have allowed minimizing missing and imputed data. For 
example, a between-assessment scale converter algorithm for 
symptom rating in schizophrenia has been developed by van 
Erp et al. (85), which enabled both researchers as clinicians to 
convert the scores of positive and negative psychotic symptoms 
assessed by the PANSS, SANS, and SAPS. Similarly, an automatic 
Phyton package called “convert” has been developed to convert 
CAARMS into SIPS scores and vice versa (36). The tool is 
freely available online at https://bitbucket.org/ioppn/convert. 
Unfortunately, we did not have the raw data on the specific 
CAARMS or SIPS (P1–P5) subscales to use this package, but 
we only had the overall severity of attenuated positive/negative 
psychotic symptoms across these two instruments. Beyond the 
diversity in the assessment instruments, there is another cause 
of suboptimal prognostic performance for our model, which 
is the baseline intrinsic difference in study populations. This is 
supported by the finding that there is substantial diversity in 
baseline risks and by the finding that our prognostic model 
had an adequate level of performance (C-statistic 0.7) in the 
subset of the largest CHR-P studies. These studies are likely to 
be those with the highest-risk enrichment and less affected by 
sampling biases which are particularly serious in the case of 
small CHR-P studies. A meta-analysis by Fusar-Poli et al. (86) 
demonstrated that these sampling biases are mostly due to the 
way CHR-P individuals are being recruited for undergoing the 
initial assessment. Specifically, recruiting CHR-P individuals 
mostly from the community would dilute the risk enrichment 
(and therefore the transition risk) compared with samples 
mostly recruited through the secondary mental health 
care system. This was also reflected by the type of outreach 
campaigns adopted by each CHR-P clinic. In comparison 
to CHR-P studies that targeted their outreach campaigns to 
health care referrers, CHR-P studies with outreach campaigns 
that were focused on the general public were associated with 
lower risk of psychosis. There was also a clear relation between 
the intensity of the campaign (amount of activities) and a 
diminished transition risk. In our IPD-MA, CHR-P studies 
differed strongly with regard to information campaigns, as 
well as sources of referrals, and this factor may have amplified 
sampling biases and reduced the prognostic performance of 
our model.
Another factor that could have modulated the prognostic 
accuracy of our model may have been the preventive treatments 
offered to the CHR-P individuals. An earlier meta-analysis (87) 
examined the preventive effects of antipsychotic medication, 
dietary supplements, integrated psychological treatments, and 
cognitive behavioral therapy on the transition to psychosis 
and reported an overall risk reduction pooled across all of 
these categories of 54% at 12 months and of 37% at 24 months. 
Individualized Prediction of Transition to PsychosisMalda et al.
13 May 2019 | Volume 10 | Article 345Frontiers in Psychiatry | www.frontiersin.org
However, the evidence remains inconclusive while a more recent 
network meta-analysis which included about 1,000 more CHR-P 
individuals found no evidence to favor specific preventive 
treatments compared with each other for the prevention of 
psychosis (88).
LIMITATIONS
One limitation of the current study is that it did not account 
for treatment effects. The majority of the included studies 
have a naturalistic, observational design, and as such are an 
adequate reflection of current clinical practice. Since subject-
level data on preventive interventions were only available for 
RCTs (51, 54, 55), the effects of these treatments could not 
be entered into the model, and as such their effects could not 
be controlled for. However, as indicated above, the actual 
effectiveness of preventive treatments for CHR-P individuals 
is questionable. As such, it is unlikely that this factor would 
have impacted our findings substantially. Another limitation 
is that documented clinical predictors in transition risk could 
not be used in our model because these were not recorded in 
the majority of the studies. These predictors are for instance 
childhood adversities, cognitive biases, social cognition, verbal 
fluency, beliefs of social marginalization, subjective complaints 
about motor functioning, urbanicity, and poor premorbid social 
adjustment. The prediction model could be improved if future 
studies into risk assessment would measure these risk factors 
systematically. The main limitation of this IPD-MA was that we 
were only able to collect a minority of the available data. Because 
of the sampling biases discussed above, this represents a major 
barrier to generalizability. It is clear that future IPD-MAs in 
CHR-P populations face the difficult challenge of collecting all 
(at least 80%) of the potential studies identified. The additional 
limitation is that we had to disregard some data because of the 
high heterogeneity of the measurements. Future IPD-MA could 
benefit from the converting strategies across different scales that 
have been discussed above here.
CLINICAL IMPLICATIONS
Given the above caveats, implementing the current prediction 
model in clinical practice is not desirable. This does not imply that 
the model is overall redundant. Future refinement of the model 
in specific clinical circumstance can be considered. For example, 
future research can clarify the characteristics of the largest studies 
in which this model can perform better. An answer to this question 
is rather complex, since these studies vary greatly with regard to 
inclusion strategies, with studies accepting self-referrals or referrals 
by friend or family (52), studies that screened in help seeking 
populations (54), as well as specialized secondary care (57). The 
offered treatments varied from none (56) to studies with different 
treatment options (52, 61). Moreover, CAYR (52) shared data of a 
relatively short follow-up period of only 1 year and a transition rate 
of 9.0%, whereas FETZ (57) monitored their participants for up to 
6 years and reported a transition rate of 44.7%.
FURTHER RESEARCH DIRECTIONS
One avenue for further research could be to investigate whether 
the prognostic quality of the current model can be optimized: 
even though a common reaction is to develop a new prediction 
model, the recommendation is to iteratively adjust the model by 
adding new data (89). The main reason for updating the available 
model is the opportunity for further improving the stability 
and generalizability of the model by considering additional 
predictors. Improving the stability of the current model would 
result in predicted outcomes less influenced by variation in 
input and enhance reliability. This updating can vary between 
simple recalibration (adjusting the intercept of the model) and 
an overall adjustment of the associations of the predictors with 
the outcome. The most obvious option for improvement could be 
found in the inclusion of data from research projects identified in 
the systematic search that have not shared their data so far. Yet, 
another possibility is that IPD-MA in CHR-P could never deliver 
robust prognostic models, because of the inherited heterogeneity 
of the underlying population, assessment measurements, and 
preventive treatments. Such a hypothesis may suggest that future 
prognostic research in the CHR-P field should rather focus on 
conducting new large-scale prospective cohort studies that are 
well characterized phenotypically.
CONCLUSION
This is the first IPD-MA in CHR-P individuals and the largest 
clinical prediction study ever conducted in these patients to 
date. There were 1,676 CHR-P individuals that have been used 
to develop and validate an individualized prognostic model 
based on clinical variables to forecast transition to psychosis. The 
model has a moderate to adequate prognostic accuracy, but there 
are potential options to improve its performance. At the same 
time, it is important to acknowledge that prognostic models 
based on IPD-MA may not be particularly effective in the CHR-P 
field. Harmonization in the CHR-P assessment instruments 
is a necessary step toward more homogenous databases that 
can support the development and validation of more robust 
prognostic models.
CONTRIBUTION TO THE FIELD
A psychotic disorder emerges mostly in adolescence and early 
adulthood and affects up to 4 in 100 individuals. The Clinical High 
Risk state for Psychosis (CHR-P) has become the cornerstone 
of modern preventive psychiatry. More recently, individualized 
prognostic models have been used to predict a transition to 
psychosis, but are typically not easily applicable in clinical 
practice, because required information to make a prediction 
requires specific equipment or training and is expensive.
In this study, we aimed to build a model to predict who will 
develop a psychosis based on information that is routinely 
collected in the clinical field. For the first time, data from 
CHR-P cohort studies worldwide were used to build this 
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model. In this study we show that our model can moderately 
predict whether an individual develops psychosis. Despite 
our positive results, it is also important to acknowledge some 
relevant limitations. Because of the large variety between the 
CHR-P studies prediction models based on IPD-MAs in this 
population may not be able to reach higher-performance 
measures. Harmonization of CHR-P assessments and 
therapeutic interventions may be the first step to facilitate 
future IPD-MAs in this field.
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